AstraZeneca and ThermoFisher to Collaborate on Companion Diagnostic Test

Published on: 
In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, February 2023, Volume 18, Issue 2

AstraZeneca and Thermo Fisher will collaborate to develop a solid tissue and blood-based companion diagnostic test for osimertinib.

Thermo Fisher Scientific and AstraZeneca announced a collaboration to develop a solid tissue and blood-based companion diagnostic (CDx) test for osimertinib (brand name Tagrisso) on Jan. 24, 2023. The CDx is intended to help identify patients with non-small cell lung cancer (NSCLC) who may be eligible for treatment with osimertinib by identifying tumors that exhibit epidermal growth factor receptor (EGFR) alterations, including exon 21 L858R mutations, exon 19 deletions, or T790M mutations.

According to a company press release, the test will use the Oncomine Dx Express Test on the Genexus Dx System, a fully integrated next-generation sequencing platform. The platform features an automated specimen-to-report workflow and can deliver results after 24 hours.

“As part of our ongoing partnership with AstraZeneca, today’s announcement will help bring targeted oncology treatments to more patients in need of new care options,” said Garret Hampton, president of clinical next-generation sequencing and oncology, Thermo Fisher Scientific, in the press release. “By leveraging the Genexus Dx System’s unprecedented turnaround time, we can help ensure molecular testing results are more readily available to inform vital treatment decisions.”


Source: Thermo Fisher Scientific